Influence of Antipsychotic and Anticholinergic Loads on Cognitive Functions in Patients with Schizophrenia

Overview

Journal Schizophr Res Treatment

Publisher Wiley

Date 2016 May 5

PMID 27144021

Citations 20

Authors

Michael Rehse

Marina Bartolovic

Katlehn Baum

Dagmar Richter

Matthias Weisbrod

Daniela Roesch-Ely

Affiliations

Soon will be listed here.

Abstract

Many patients with schizophrenia show cognitive impairment. There is evidence that, beyond a certain dose of antipsychotic medication, the antipsychotic daily dose (ADD) may impair cognitive performance. Parallel to their D2 receptor antagonism, many antipsychotics show a significant binding affinity to cholinergic muscarinic receptors. Pharmacological treatment with a high anticholinergic daily dose (CDD) significantly impairs attention and memory performance. To examine the relationships between individual cognitive performance and ADD and/or CDD, we conducted a retrospective record-based analysis of a sample of n = 104 in patients with a diagnosis of schizophrenia, all of whom had completed a comprehensive neuropsychological test battery. To calculate the individual ADD and CDD, the medication at the time of testing was converted according to equivalence models. After extracting five principal cognitive components, we examined the impact of ADD and CDD on cognitive performance in the medicated sample and subgroups using multiple regression analysis. Finally, locally weighted scatterplot smoothing (Loess) was applied to further explore the course of cognitive performance under increasing dosage. Results showed significant negative effects of ADD on performance in tests of information processing speed and verbal memory. No effects were found for CDD. The potential neuropsychopharmacological and clinical implications are discussed.

Citing Articles

Semantic abnormalities in schizophrenia and bipolar disorder: A natural language processing approach.

Jo Y, Joo Y Sci Prog. 2025; 108(1):368504241308309.

PMID: 39846293 PMC: 11758559. DOI: 10.1177/00368504241308309.

Impact of Anticholinergic Burden on Cognitive Functions in Individuals with Bipolar Disorder, Schizoaffective Disorder, and Schizophrenia.

Oktar Erdogan N, Yucens B, Tumkaya S Clin Psychopharmacol Neurosci. 2025; 23(1):76-85.

PMID: 39820114 PMC: 11747743. DOI: 10.9758/cpn.24.1184.

Drug-Induced Cognitive Impairment.

Reimers A, Odin P, Ljung H Drug Saf. 2024; 48(4):339-361.

PMID: 39718691 PMC: 11903592. DOI: 10.1007/s40264-024-01506-5.

Biomarkers of neurodegeneration in schizophrenia: systematic review and meta-analysis.

Wilson J, Liu K, Jones K, Mahmood J, Arya U, Howard R BMJ Ment Health. 2024; 27(1.

PMID: 38796179 PMC: 11129036. DOI: 10.1136/bmjment-2024-301017.

Anticholinergic load: A commonly neglected and preventable risk to cognition during schizophrenia treatment?.

Martinez-Cao C, Garcia-Fernandez A, Gonzalez-Blanco L, Saiz P, Bobes J, Garcia-Portilla M Schizophr Res Cogn. 2024; 37:100317.

PMID: 38745931 PMC: 11092394. DOI: 10.1016/j.scog.2024.100317.

References

Choi K, Wykes T, Kurtz M . Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy. Br J Psychiatry. 2013; 203(3):172-8. PMC: 3759029. DOI: 10.1192/bjp.bp.111.107359. View

Heaton R, Gladsjo J, Palmer B, Kuck J, Marcotte T, Jeste D . Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry. 2001; 58(1):24-32. DOI: 10.1001/archpsyc.58.1.24. View

Tandberg M, Ueland T, Sundet K, Haahr U, Joa I, Johannessen J . Neurocognition and occupational functioning in patients with first-episode psychosis: a 2-year follow-up study. Psychiatry Res. 2011; 188(3):334-42. DOI: 10.1016/j.psychres.2011.04.021. View

Sarter M, Hasselmo M, Bruno J, Givens B . Unraveling the attentional functions of cortical cholinergic inputs: interactions between signal-driven and cognitive modulation of signal detection. Brain Res Brain Res Rev. 2005; 48(1):98-111. DOI: 10.1016/j.brainresrev.2004.08.006. View

Baker L, Cheng L, Amara I . The withdrawal of benztropine mesylate in chronic schizophrenic patients. Br J Psychiatry. 1983; 143:584-90. DOI: 10.1192/bjp.143.6.584. View

MacDonald S, Cervenka S, Farde L, Nyberg L, Backman L . Extrastriatal dopamine D2 receptor binding modulates intraindividual variability in episodic recognition and executive functioning. Neuropsychologia. 2009; 47(11):2299-304. DOI: 10.1016/j.neuropsychologia.2009.01.016. View

Lehman A, Kreyenbuhl J, Buchanan R, Dickerson F, Dixon L, Goldberg R . The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull. 2004; 30(2):193-217. DOI: 10.1093/oxfordjournals.schbul.a007071. View

Kawai N, Yamakawa Y, Baba A, Nemoto K, Tachikawa H, Hori T . High-dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose-reduction. Prog Neuropsychopharmacol Biol Psychiatry. 2006; 30(6):1009-14. DOI: 10.1016/j.pnpbp.2006.03.013. View

Vinogradov S, Fisher M, Warm H, Holland C, Kirshner M, Pollock B . The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am J Psychiatry. 2009; 166(9):1055-62. PMC: 3735363. DOI: 10.1176/appi.ajp.2009.09010017. View

10.

Shekhar A, Potter W, Lightfoot J, Lienemann J, Dube S, Mallinckrodt C . Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry. 2008; 165(8):1033-9. DOI: 10.1176/appi.ajp.2008.06091591. View

11.

Woodward N, Purdon S, Meltzer H, Zald D . A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr Res. 2006; 89(1-3):211-24. DOI: 10.1016/j.schres.2006.08.021. View

12.

Elie D, Poirier M, Chianetta J, Durand M, Gregoire C, Grignon S . Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder. J Psychopharmacol. 2009; 24(7):1037-44. DOI: 10.1177/0269881108100777. View

13.

Tost H, Meyer-Lindenberg A, Klein S, Schmitt A, Hohn F, Tenckhoff A . D2 antidopaminergic modulation of frontal lobe function in healthy human subjects. Biol Psychiatry. 2006; 60(11):1196-205. DOI: 10.1016/j.biopsych.2006.04.014. View

14.

Saeedi H, Remington G, Christensen B . Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood. Schizophr Res. 2006; 85(1-3):222-31. DOI: 10.1016/j.schres.2006.03.033. View

15.

Minzenberg M, Poole J, Benton C, Vinogradov S . Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry. 2004; 161(1):116-24. DOI: 10.1176/appi.ajp.161.1.116. View

16.

Vernaleken I, Kumakura Y, Buchholz H, Siessmeier T, Hilgers R, Bartenstein P . Baseline [18F]-FDOPA kinetics are predictive of haloperidol-induced changes in dopamine turnover and cognitive performance: A positron emission tomography study in healthy subjects. Neuroimage. 2008; 40(3):1222-31. DOI: 10.1016/j.neuroimage.2007.12.045. View

17.

Lin C, Chen W, Lin C, Lee M, Ko M, Li C . Predictors of psychiatric readmissions in the short- and long-term: a population-based study in Taiwan. Clinics (Sao Paulo). 2010; 65(5):481-9. PMC: 2882542. DOI: 10.1590/S1807-59322010000500005. View

18.

Michalopoulou P, Lewis S, Wykes T, Jaeger J, Kapur S . Treating impaired cognition in schizophrenia: the case for combining cognitive-enhancing drugs with cognitive remediation. Eur Neuropsychopharmacol. 2013; 23(8):790-8. DOI: 10.1016/j.euroneuro.2013.03.012. View

19.

Bilder R, Goldman R, Robinson D, Reiter G, Bell L, Bates J . Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry. 2000; 157(4):549-59. DOI: 10.1176/appi.ajp.157.4.549. View

20.

Wykes T, Huddy V, Cellard C, McGurk S, Czobor P . A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry. 2011; 168(5):472-85. DOI: 10.1176/appi.ajp.2010.10060855. View